tetano
Editor, Senior Moderator
J Med Virol. 2015 Aug 12. doi: 10.1002/jmv.24351. [Epub ahead of print]
[h=1]Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.[/h] Souza TM[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Santini-Oliveira M[SUP]4[/SUP], Martorelli A[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Luz PR[SUP]4[/SUP], Vasconcellos MT[SUP]4[/SUP], Giacoia-Gripp CB[SUP]5[/SUP], Morgado M[SUP]5[/SUP], Nunes EP[SUP]4[/SUP], Lemos AS[SUP]4[/SUP], Ferreira AC[SUP]4[/SUP], Moreira RI[SUP]4[/SUP], Veloso VG[SUP]4[/SUP], Siqueira M[SUP]1[/SUP], Grinsztejn B[SUP]4[/SUP], Camacho LA[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] HIV-infected individuals have a higher risk of serious illnesses following infection by infection with influenza. Although anti-influenza vaccination is recommended, immunosuppression may limit their response to active immunization. We followed-up a cohort of HIV-infected individuals vaccinated against influenza to assess the immunogenicity and sustainability of the immune response to vaccination. Individuals were vaccinated 2011 with inactivated triple influenza vaccine (TIV), and they had received in 2010 the monovalent anti-A(H1N1)pdm09 vaccine. The sustainability of the immune response to A(H1N1)pdm09 at 12 months after monovalent vaccination fell, both in individuals given two single or two double doses. For these individuals, A(H1N1)pdm09 component from TIV acted as a booster, raising around 40% the number of seroprotected individuals. Almost 70% of the HIV-infected individuals were already seroprotected to A/H3N2 at baseline. Again, TIV boosted over 90% the seroprotection to A/H3N2. Anti-A/H3N2 titers dropped by 20% at 6 months after vaccination. Pre-vaccination seroprotection rate to influenza B (victoria lineage) was the lowest among those tested, seroconversion rates were higher after vaccination. Seroconversion/protection after TIV vaccination did not differ significantly across categories of clinical and demographic variables. Anti-influenza responses in Brazilian HIV-infected individuals reflected both the previous history of virus circulation in Brazil and vaccination. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] HIV; Influenza; immunogenicity; vaccine; vaccine mismatch
PMID: 26267817 [PubMed - as supplied by publisher]
[h=1]Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.[/h] Souza TM[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Santini-Oliveira M[SUP]4[/SUP], Martorelli A[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Luz PR[SUP]4[/SUP], Vasconcellos MT[SUP]4[/SUP], Giacoia-Gripp CB[SUP]5[/SUP], Morgado M[SUP]5[/SUP], Nunes EP[SUP]4[/SUP], Lemos AS[SUP]4[/SUP], Ferreira AC[SUP]4[/SUP], Moreira RI[SUP]4[/SUP], Veloso VG[SUP]4[/SUP], Siqueira M[SUP]1[/SUP], Grinsztejn B[SUP]4[/SUP], Camacho LA[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] HIV-infected individuals have a higher risk of serious illnesses following infection by infection with influenza. Although anti-influenza vaccination is recommended, immunosuppression may limit their response to active immunization. We followed-up a cohort of HIV-infected individuals vaccinated against influenza to assess the immunogenicity and sustainability of the immune response to vaccination. Individuals were vaccinated 2011 with inactivated triple influenza vaccine (TIV), and they had received in 2010 the monovalent anti-A(H1N1)pdm09 vaccine. The sustainability of the immune response to A(H1N1)pdm09 at 12 months after monovalent vaccination fell, both in individuals given two single or two double doses. For these individuals, A(H1N1)pdm09 component from TIV acted as a booster, raising around 40% the number of seroprotected individuals. Almost 70% of the HIV-infected individuals were already seroprotected to A/H3N2 at baseline. Again, TIV boosted over 90% the seroprotection to A/H3N2. Anti-A/H3N2 titers dropped by 20% at 6 months after vaccination. Pre-vaccination seroprotection rate to influenza B (victoria lineage) was the lowest among those tested, seroconversion rates were higher after vaccination. Seroconversion/protection after TIV vaccination did not differ significantly across categories of clinical and demographic variables. Anti-influenza responses in Brazilian HIV-infected individuals reflected both the previous history of virus circulation in Brazil and vaccination. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] HIV; Influenza; immunogenicity; vaccine; vaccine mismatch
PMID: 26267817 [PubMed - as supplied by publisher]